News | Artificial Intelligence | May 31, 2022

With Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy and radiomics

With Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy and radiomics

May 31, 2022 — Median Technologies announces that the company is expanding its portfolio of services with Imaging Lab, a new entity whose mission is to leverage AI, data mining, and radiomics technologies to exploit imaging data from clinical trials in oncology.

The creation of Imaging Lab materializes the convergence of iCRO's activities for image management in the development of new oncologic drugs and iBiopsy's activities for the development of software as medical device targeting early diagnosis of cancers, especially lung cancer.

"We are seeing a paradigm shift of pharmaceutical companies towards new drug candidates targeting patients with early-stage cancers," said Fredrik Brag, CEO and founder of Median Technologies. "The synergy between our iCRO and iBiopsy businesses is perfect to respond to this change: iBiopsy develops software as medical device, integrating AI technologies, which allow the diagnosis of diseases at a very early stage, when patients are still asymptomatic. At the same time, iCRO has extensive knowledge of image processing and its management in clinical trials. The cross-fertilization of our two businesses will enable us to leverage imaging data in conjunction with other clinical information in an unparalleled way and provide biopharmaceutical companies with tools for Go/No-Go decisions in trials," adds Fredrik Brag.

Imaging Lab will provide new answers in four areas that determine the success of clinical trials: selection of patients included in trials, especially inclusion of patients diagnosed at early stages of disease thanks to AI technologies, prediction of response to therapy, measurement of disease progression, and evaluation of the safety of drug candidates. The goal is to optimize development plans, including facilitating Go/No-Go decisions to increase the success rate of clinical trials. This rate is especially low in oncology, generating an average development cost of $2.8 billion to take a new molecule to market, compared with an average of $1 billion per new molecule brought to market for other therapeutic areas[1].

"Our experience of image management in clinical trials has shown that trial data is vastly underutilized. We can extract much more information from images through the widescale use of data mining, AI, and radiomics and use these technologies to better support our customers and biopharmaceutical partners in their clinical developments," says Nicolas Dano, COO iCRO of Median Technologies.

The Imaging Lab team will be present from June 4-6 (exhibition dates) at the ASCO Annual Conference in Chicago , Median’s booth #2098, Exhibit Hall A, to meet the pharmaceutical community.

For more information: www.mediantechnologies.com

Reference:

[1] https://www.biopharmadive.com/news/new-drug-cost-research-development-market-jama-study/573381/


Related Content

News | Magnetic Resonance Imaging (MRI)

July 2, 2025 — Philips has received FDA 510(k) clearance for SmartSpeed Precise[1] MR’s latest deep learning ...

Time July 03, 2025
arrow
News | Ultrasound Imaging

July 1, 2025 — UPDATE: The final paper is now available at: JMIR AI - ChatGPT-4–Driven Liver Ultrasound Radiomics ...

Time July 01, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

June 26, 2025 — Siemens Healthineers has received Food and Drug Administration clearance for the Magnetom Flow.Ace, its ...

Time June 26, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | Bone Densitometry Systems

June 19, 2025 — Naitive Technologies has published results demonstrating the diagnostic performance of its AI-powered ...

Time June 18, 2025
arrow
News | Lung Imaging

June 18, 2025 — Exo recently announced that now included on its Exo Iris is the first ever FDA 510(k) cleared AI for ...

Time June 18, 2025
arrow
News | Digital Pathology

June 11, 2025 — Diagnostic laboratory leaders view digital pathology and artificial intelligence (AI) as pivotal to ...

Time June 12, 2025
arrow
News | Lung Imaging

June 11, 2025 — To prepare healthcare workforces and providers for an AI-driven future, Qure.ai has expanded its Global ...

Time June 11, 2025
arrow
News | Radiology Imaging

June 10, 2025 — CIVIE has announced the official launch of RadPod, an AI-driven, on-demand radiology platform designed ...

Time June 10, 2025
arrow
Subscribe Now